Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Document Type
Article
Publication Date
2-17-2024
Publication Title
Lancet
Keywords
Humans; Adjuvants, Immunologic; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Melanoma; Skin Neoplasms; oregon; chiles
Abstract
BACKGROUND: Checkpoint inhibitors are standard adjuvant treatment for stage IIB-IV resected melanoma, but many patients recur. Our study aimed to evaluate whether mRNA-4157 (V940), a novel mRNA-based individualised neoantigen therapy, combined with pembrolizumab, improved recurrence-free survival and distant metastasis-free survival versus pembrolizumab monotherapy in resected high-risk melanoma.
METHODS: We did an open-label, randomised, phase 2b, adjuvant study of mRNA-4157 plus pembrolizumab versus pembrolizumab monotherapy in patients, enrolled from sites in the USA and Australia, with completely resected high-risk cutaneous melanoma. Patients with completely resected melanoma (stage IIIB-IV) were assigned 2:1 to receive open-label mRNA-4157 plus pembrolizumab or pembrolizumab monotherapy. mRNA-4157 was administered intramuscularly (maximum nine doses) and pembrolizumab intravenously (maximum 18 doses) in 3-week cycles. The primary endpoint was recurrence-free survival in the intention-to-treat population. This ongoing trial is registered at ClinicalTrials.gov, NCT03897881.
FINDINGS: From July 18, 2019, to Sept 30, 2021, 157 patients were assigned to mRNA-4157 plus pembrolizumab combination therapy (n=107) or pembrolizumab monotherapy (n=50); median follow-up was 23 months and 24 months, respectively. Recurrence-free survival was longer with combination versus monotherapy (hazard ratio [HR] for recurrence or death, 0·561 [95% CI 0·309-1·017]; two-sided p=0·053), with lower recurrence or death event rate (24 [22%] of 107 vs 20 [40%] of 50); 18-month recurrence-free survival was 79% (95% CI 69·0-85·6) versus 62% (46·9-74·3). Most treatment-related adverse events were grade 1-2. Grade ≥3 treatment-related adverse events occurred in 25% of patients in the combination group and 18% of patients in the monotherapy group, with no mRNA-4157-related grade 4-5 events. Immune-mediated adverse event frequency was similar for the combination (37 [36%]) and monotherapy (18 [36%]) groups.
INTERPRETATION: Adjuvant mRNA-4157 plus pembrolizumab prolonged recurrence-free survival versus pembrolizumab monotherapy in patients with resected high-risk melanoma and showed a manageable safety profile. These results provide evidence that an mRNA-based individualised neoantigen therapy might be beneficial in the adjuvant setting.
FUNDING: Moderna in collaboration with Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA.
Clinical Institute
Cancer
Department
Oncology
Department
Dermatology
Recommended Citation
Weber, Jeffrey S; Carlino, Matteo S; Khattak, Adnan; Meniawy, Tarek; Ansstas, George; Taylor, Matthew H; Kim, Kevin B; McKean, Meredith; Long, Georgina V; Sullivan, Ryan J; Faries, Mark; Tran, Thuy T; Cowey, C Lance; Pecora, Andrew; Shaheen, Montaser; Segar, Jennifer; Medina, Theresa; Atkinson, Victoria; Gibney, Geoffrey T; Luke, Jason J; Thomas, Sajeve; Buchbinder, Elizabeth I; Healy, Jane A; Huang, Mo; Morrissey, Manju; Feldman, Igor; Sehgal, Vasudha; Robert-Tissot, Celine; Hou, Peijie; Zhu, Lili; Brown, Michelle; Aanur, Praveen; Meehan, Robert S; and Zaks, Tal, "Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study." (2024). Articles, Abstracts, and Reports. 8465.
https://digitalcommons.providence.org/publications/8465
